
Michael Bronstein
Articles
-
Oct 27, 2024 |
marijuanamoment.net | Michael Bronstein
“Misleading marketing, which frames synthetic THC as a ‘hemp product,’ tricks buyers into thinking they are purchasing something natural and safe.”By Michael Bronstein, American Trade Association for Cannabis and Hemp (ATACH)In a recent op-ed by the Reason Foundation titled “Banning Hemp Products Isn’t The Way to Protect Public Health,” the author correctly makes the case that bans are often ineffective and can push consumers toward more dangerous, unregulated markets.
-
Sep 6, 2024 |
mjbizdaily.com | Michael Bronstein |Kate Lavin
(This contributed guest column is part of the cover package in the September-October issue of MJBizMagazine. To be considered as an MJBizDaily guest columnist, please submit your request here.)The U.S. Congress is caught up in a political haze over what to do with hemp. In 2018, Congress was told hemp laws were for “rope, not dope.”But the industry’s hemp debate today is entirely about dope.
-
Mar 18, 2024 |
towardsdatascience.com | Michael Bronstein
AI-first BiotechThis year marks perhaps the zenith of expectations for AI-based breakthroughs in biology, transforming it into an engineering discipline that is programmable, predictable, and replicable. Drawing insights from AI breakthroughs in perception, natural language, and protein structure prediction, we endeavour to pinpoint the characteristics of biological problems that are most conducive to being solved by AI techniques.
-
Jan 8, 2024 |
biorxiv.org | Guadalupe Gonzalez |Guadalupe E González |Isuru Herath |Kirill Veselkov |Michael Bronstein
AbstractAs an alternative to target-driven drug discovery, phenotype-driven approaches identify compounds that counteract the overall disease effects by analyzing phenotypic signatures. Our study introduces a novel approach to this field, aiming to expand the search space for new therapeutic agents. We introduce PDGrapher, a causally-inspired graph neural network model designed to predict arbitrary perturbagens - sets of therapeutic targets - capable of reversing disease effects.
-
Jan 3, 2024 |
biorxiv.org | Guadalupe Gonzalez |Guadalupe E González |Kirill Veselkov |Michael Bronstein |Isuru Herath
AbstractPhenotype-driven drug discovery, as an emerging alternative to target-driven strategies, identifies compounds that counteract the overall effects of diseases by analyzing phenotypic signatures. Our study introduces a novel approach to this field, aiming to expand the search space for new therapeutic agents. We introduce PDGrapher, a causally-inspired graph neural network model designed to predict arbitrary perturbagens - a set of therapeutic targets - capable of reversing disease effects.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →